|
gptkbp:instanceOf
|
gptkb:law
|
|
gptkbp:affects
|
medical research
biotech industry
genetic diagnostics
|
|
gptkbp:arguedDate
|
2013-04-15
|
|
gptkbp:citation
|
gptkb:569_U.S._576
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:date
|
2013-06-13
|
|
gptkbp:decidedBy
|
gptkb:Supreme_Court_of_the_United_States
|
|
gptkbp:defendant
|
gptkb:Myriad_Genetics,_Inc.
|
|
gptkbp:docketNumber
|
12-398
|
|
gptkbp:heldBy
|
Naturally occurring DNA sequences cannot be patented
cDNA is patent eligible
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Myriad Genetics case
|
|
gptkbp:legalImpact
|
invalidated gene patents on naturally occurring DNA
|
|
gptkbp:lowerAward
|
gptkb:United_States_Court_of_Appeals_for_the_Federal_Circuit
|
|
gptkbp:lowerCourtDecision
|
affirmed in part, reversed in part
|
|
gptkbp:officialName
|
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.
|
|
gptkbp:opinionBy
|
gptkb:Justice_Clarence_Thomas
|
|
gptkbp:plaintiff
|
gptkb:Association_for_Molecular_Pathology
|
|
gptkbp:predecessor
|
gene patenting cases
|
|
gptkbp:relatedTo
|
gptkb:biotechnology
gptkb:intellectual_property
genetic testing
|
|
gptkbp:subject
|
gptkb:BRCA1_gene
gptkb:US_patent
gptkb:BRCA2_gene
human genes
|
|
gptkbp:unanimousDecision
|
true
|
|
gptkbp:bfsParent
|
gptkb:Association_for_Molecular_Pathology_v._Myriad_Genetics,_Inc.
|
|
gptkbp:bfsLayer
|
8
|